ClinicalTrials.gg
CompletedNCT02280616Updated Jan 21, 2016

Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis

A Phase 2 interventional study of low dose budesonide tablet and high dose budesonide tablet in Eosinophilic Esophagitis, sponsored by Dr. Falk Pharma GmbH. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-01-21.

Sponsored by Dr. Falk Pharma GmbH · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 18 studies testing budesonide in Eosinophilic Esophagitis — 1 open to participants now, 2 under way, 1 of them phase 3. Budesonide · Eosinophilic Esophagitis.

Enrollment
10th of 18
76 · median 79
Started
2011
the only one that year
Phase 2
7 of 18
none open now
Registered
9th of 18
by date
Lead sponsor
4 of 18
Dr. Falk Pharma GmbH

Among the 18 studies testing budesonide in Eosinophilic Esophagitis, this one is the 10th largest by enrollment, is the only one that started in 2011, is one of 7 in phase 2, and was the 9th registered.

Eosinophilic Esophagitis

235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.

Browse Eosinophilic Esophagitis studies →

Open to participants now

1 of the 18 studies testing budesonide in Eosinophilic Esophagitis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 42 Eosinophilic Esophagitis studies recruiting now, 12 (29%) set no upper age limit and 27 (64%) stop at 75 or younger; 27 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing budesonide in Eosinophilic Esophagitis, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy of a low and high dose of a budesonide effervescent tablet and oral viscous budesonide suspension vs. placebo for the induction treatment of active eosinophilic esophagitis.

03

Conditions studied

  • Eosinophilic Esophagitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major Inclusion Criteria:

  • Signed
  • Male or female patients, 18 to 75 years of age
  • Confirmed clinicopathological diagnosis of EoE according to established diagnostic criteria:

(A) Clinical symptoms of esophageal dysfunction (B) Peak eosinophils ≥ 15 in at least 1 high-power field (hpf)

  • Active symptomatic and histological EoE at baseline

Major Exclusion Criteria:

  • Clinically and endoscopically suspicion for gastroesophageal reflux disease, achalasia, or sklerodermia
  • Gastroesophageal reflux disease and PPI-responsive esophageal eosinophilia
  • Other clinical evident causes than EoE for esophageal eosinophilia
  • Any concomitant esophageal disease and relevant gastro-intestinal disease (celiac disease, inflammatory bowel disease, oropharyngeal or esophageal bacterial, viral, or fungal infection)
  • Any relevant systemic disease (e.g., AIDS, active tuberculosis)
  • Abnormal hepatic function at screening visit, liver cirrhosis, or portal hypertension
  • Abnormal renal function at screening
  • History of cancer in the last five years (except for non- cancers, e.g., basalioma)
  • History of esophageal surgery at any time or of esophageal dilation procedures within the last 8 weeks prior to screening visit
  • Upper gastrointestinal bleeding within 8 weeks prior to screening visit
  • Concomitant, or within the 4 weeks prior to screening visit, treatment with systemic therapies for any reason that may affect assessment of primary and secondary endpoints, i.e., systemic , histamine antagonists, mast cell stabilizers, leukotriene receptor antagonists, biologics, or
  • Concomitant, or within the 2 weeks prior to screening visit, treatment with topical therapies for any reason that may affect assessment of primary and secondary endpoints, i.e., topical glucocorticoids or inhaled sodium cromoglycate
  • Installation of dietary restrictions within 4 weeks prior to screening visit or during treatment
  • Intake of grapefruit containing food or beverages during the treatment with study medication
  • Known intolerance/ to study drug
  • Existing or intended pregnancy or breast-feeding
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Low dose budesonide tablet

    Drug: low dose budesonide tablet

  • Experimental
    High dose budesonide tablet

    Drug: high dose budesonide tablet

  • Experimental
    High dose budesonide suspension

    Drug: high dose budesonide suspension

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 1mg budesonide tablet twice daily AND 5ml placebo suspension twice daily

    Also known as: BET 1mg BID

  • 2mg budesonide tablet twice daily AND 5ml placebo suspension twice daily

    Also known as: BET 2mg BID

  • placebo tablet twice daily AND 5ml \[0.4mg budesonide/ml\] suspension twice daily

    Also known as: BVS 2mg BID

  • DrugPlacebo

    placebo tablet twice daily AND 5ml placebo suspension twice daily

06

What researchers measure

Primary outcomes

  1. Rate of histological remission

    Time frame: 2 weeks (LOCF)

  2. Change in the mean numbers of eos

    Time frame: 2 weeks (LOCF)

Secondary outcomes

  1. Change in the mean numbers of eos

    Time frame: 2 weeks (LOCF)

07

Study locations

1 site
  • Center for Digestive Diseases Eppendorf
    Hamburg, 20249, Germany
08

References and documents

Publications

  • Miehlke S, Hruz P, Vieth M, Bussmann C, von Arnim U, Bajbouj M, Schlag C, Madisch A, Fibbe C, Wittenburg H, Allescher HD, Reinshagen M, Schubert S, Tack J, Muller M, Krummenerl P, Arts J, Mueller R, Dilger K, Greinwald R, Straumann A. A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis. Gut. 2016 Mar;65(3):390-9. doi: 10.1136/gutjnl-2014-308815. Epub 2015 Mar 19. PubMed 25792708 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Apr 2013 and a completion of May 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2014
First posted
Oct 31, 2014
Start
Jun 2011
Primary completionActual
Apr 2013
CompletionActual
May 2014
Last update
Jan 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02280616
Responsible party
Sponsor
First posted
Oct 31, 2014
Start date
Jun 2011
Primary completion
Apr 2013
Completion
May 2014
Last update
Jan 21, 2016

Study contacts

Ralph Mueller, PhD
study director · Dr. Falk Pharma GmbH

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion